Status:
ACTIVE_NOT_RECRUITING
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
Lead Sponsor:
Exact Sciences Corporation
Collaborating Sponsors:
NSABP Foundation Inc
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Maximum duration of participant participation is up ...
Eligibility Criteria
Inclusion
- Diagnosis of carcinoma of the colon or rectum (patients with lymphomatous, sarcomatous, or neuroendocrine features are not eligible).
- Post complete surgical resection of CRC, with last surgery occurring within 180 days prior to enrollment are eligible if all of the following conditions are met:
- in the opinion of the surgeon, all grossly visible tumor was completely resected ("curative resection") and
- histologic evaluation by the pathologist confirms the margins of the resected specimens are not involved by malignant cells.
- i. Patients with T4 tumors that have involved an adjacent structure (e.g., bladder, small intestine, ovary, etc.) by direct extension from the primary tumor must have had all or a portion of the adjacent structure removed en bloc with the primary tumor and local radiation therapy will not be utilized.
- Pathologic stage II or III
- ECOG performance status ≤ 2 (0, 1 or 2).
- Able to understand and provide informed consent.
- Willing and able to comply with the study requirements, which includes the collection of approximately 43mL of blood for each research blood draw.
Exclusion
- Initiated adjuvant therapy for current CRC diagnosis (note: prior neoadjuvant therapy acceptable).
- Pregnant or breastfeeding at time of enrollment.
- Prior history of any invasive cancer (including CRC) within the past 3 years prior to informed consent, with the exception of non-melanoma skin cancer. Patients with a prior history of noninvasive (in situ) carcinomas may participate after definitive treatment.
- Prior transplant history:
- Prior allogeneic hematopoietic stem cell transplant at any time.
- Prior solid organ transplant within the last 2 years prior to enrollment.
- Multiple cancer diagnoses: Synchronous or asynchronous diagnoses (or suspicion) of multiple primary cancers at the time of eligibility screening.
Key Trial Info
Start Date :
December 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 15 2027
Estimated Enrollment :
1017 Patients enrolled
Trial Details
Trial ID
NCT05210283
Start Date
December 15 2021
End Date
February 15 2027
Last Update
July 28 2025
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
Facey Medical Group - Mission Hills - Endoscopy Center & Gastroenterology
Mission Hills, California, United States, 91345
2
Torrance Memorial Hunt Cancer Institute
Torrance, California, United States, 90505
3
University of Florida Division of Hematology & Oncology
Gainesville, Florida, United States, 32610
4
Mount Sinai Medical - Comprehensive Cancer Center
Miami Beach, Florida, United States, 33140